CTHRepealedLegislation
National Health (Weighted average disclosed price - supplementary disclosure cycle B) Determination 2013 (No. PB 55 of 2013)
4Weighted average disclosed price for brands of pharmaceutical items – unadjusted price reduction is at least 10%
Start here
Get a plain-English read of 4
Turn the raw legal text into a practical explanation grounded in National Health (Weighted average disclosed price - supplementary disclosure cycle B) Determination 2013 (No. PB 55 of 2013).
4 Weighted average disclosed price for brands of pharmaceutical items – unadjusted price reduction is at least 10%
For subsection 99ADB(4) of the Act, the weighted average disclosed price specified in column 3 of an item in Schedule 1 is the weighted average disclosed price for the brand of pharmaceutical item specified in column 2 of the same item in Schedule 1.